Press Releases
Stay informed about the newest developments at Genescopy and explore how we are revolutionizing gastrointestinal health.
Find out more
Stay informed about the newest developments at Genescopy and explore how we are revolutionizing gastrointestinal health.
Gary Gallimore, Chief Technology and Information Officer, is a seasoned technology executive with more than 25 years of experience leading high-performing engineering and IT organizations across the semiconductor, telecommunications, and healthcare industries. He also serves as Chief Security Officer, overseeing enterprise-wide cybersecurity strategy and ensuring compliance with regulatory requirements and industry standards.
Most recently, Gary served as Senior Director of Software Engineering at Genomic Health, an Exact Sciences company, where he led engineering efforts supporting research and product development for the Oncotype DX Breast Cancer assay, a leading molecular diagnostic test. He brings a strong combination of strategic vision and business acumen, with deep expertise in in vitro diagnostics (IVD), laboratory-developed tests (LDTs), and medical device development.
Throughout his career, Gary has held multiple engineering leadership roles with responsibility for product innovation, operational excellence, and successful commercialization initiatives. He holds a Bachelor of Science in Electronic Engineering Technology from DeVry University and has pursued additional studies at the University of California, Santa Cruz; the University of California, Berkeley; and Santa Clara University.
Amit Bhalla brings over 25 years of experience in the healthcare industry to his role as Chief Financial Officer at Geneoscopy. Most recently, he served as Executive Vice President and Chief Financial Officer of Sampled (formerly Infinity BiologiX), a global biorepository that supports academia, government, and biopharma, where he led all aspects of finance operations as well as supply chain and facilities functions. Amit also held the position of Vice President of Global Strategy & Development and was a member of the Executive Management Committee at Becton Dickinson.
On Wall Street, Amit was the lead healthcare analyst for Lord Abbett’s Value Funds, Director of Equity Research at Citi, and Vice President at Morgan Stanley, where he served as the senior analyst responsible for overseeing the Life Science Tools, Diagnostics, and Medical Device industries. His work has frequently been quoted in major financial publications, and he was consistently ranked among the top analysts on Wall Street by Forbes, Institutional Investor, and Starmine/Financial Times. Amit earned his Bachelor of Science degree in Neurobiology from Cornell University and an MBA from Carnegie Mellon’s Tepper School of Business.
Matt Sargent, Chief Commercial Officer, brings 20 years of experience leading high-performance commercial teams in the oncology space. Most recently, he served as Chief Business Officer at Harbinger Health, responsible for business development related to the company’s blood-based cancer early detection test. Before Harbinger Health, he was Vice President of Commercial Oncology at Hologic, responsible for sales, commercial strategy, and business development for the CLIA oncology diagnostics service business, following Hologic’s acquisition of Biotheranostics, where he served as Chief Commercial Officer. Matt holds a B.S. degree in Anatomy and Animal Physiology from Cornell University, an M.S. degree in Cancer Physiology from the University of Buffalo, Roswell Park Cancer Institute Graduate Division, and an M.B.A. degree from Pepperdine University.
Co-founder of Geneoscopy, Andrew graduated from Cornell University with a Bachelor’s degree in Applied Economics & Management and a specialization in Finance. He received an MBA in Health Care Management and Entrepreneurial Management from The Wharton School.
Andrew began his career as a financial analyst in J.P. Morgan’s healthcare investment banking group, working primarily on M&A and capital markets transactions. Andrew also worked as an associate at Lindsay Goldberg, a middle-market private equity firm focused on partnering with family-owned businesses.
Dr. Erica Barnell is the co-founder and Chief Medical & Science Officer of Geneoscopy. She earned her MD/PhD at Washington University School of Medicine in 2023, completing her doctoral work in Molecular Genetics and Genomics from the McDonnell Genome Institute. Dr. Barnell spearheaded the clinical and regulatory development of ColoSense®, Geneoscopy’s flagship diagnostic, and the first FDA-approved RNA-based stool test for colorectal cancer screening in adults aged 45 and older.
Her work extends beyond colorectal cancer, advancing the application of non-invasive stool RNA technology to monitor disease activity and predict therapeutic response in inflammatory bowel disease. A recognized leader in precision medicine and an advocate for health equity, Dr. Barnell holds multiple patents and has authored numerous peer-reviewed publications. She was named to Forbes’ 30 Under 30 in 2020, and is a frequent speaker on innovation, leadership, and championing women in STEM.
